---
title: Lycia Therapeutics (LYCA) Eyes $250 Million IPO to Advance Protein-Degrading Medicines
description: Early allergy data supports its novel approach, but an $886 million proposed valuation puts the focus on translating IgE reductions into meaningful patient benefits.
image: https://blog.ipoprophet.com/hubfs/LYCIA%20Thumbnail.jpg
---

[Skip to content](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/lycia-therapeutics-lyca-eyes-250-million-ipo-to-advance-protein-degrading-medicines#main-content)

[![IPO\_PROPHET\_BLUE logo](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_BLUE%20logo.png?width=2973&height=302&name=IPO_PROPHET_BLUE%20logo.png)](https://www.IPOProphet.com)

- [Login](https://app.ipoprophet.com/login)

Open main navigation

Close main navigation

- [Login](https://app.ipoprophet.com/login)

[Subscribe to our Newsletter](https://share.hsforms.com/1xXldKrGiQBCbNmtOz6j4Jwq3cu4)

[Go Back to Home](http://www.ipoprophet.com/)

[Go Back to Blog](http://www.ipoprophet.com/blog)

 Oct 21, 2026, 3:17:28 PM

# Lycia Therapeutics (LYCA) Eyes $250 Million IPO to Advance Protein-Degrading Medicines

![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman)

Share: [facebook-f icon](http://www.facebook.com/share.php?u=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/lycia-therapeutics-lyca-eyes-250-million-ipo-to-advance-protein-degrading-medicines) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/lycia-therapeutics-lyca-eyes-250-million-ipo-to-advance-protein-degrading-medicines) [Twitter icon](https://twitter.com/intent/tweet?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/lycia-therapeutics-lyca-eyes-250-million-ipo-to-advance-protein-degrading-medicines) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/lycia-therapeutics-lyca-eyes-250-million-ipo-to-advance-protein-degrading-medicines) [envelope icon](mailto:?body=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/lycia-therapeutics-lyca-eyes-250-million-ipo-to-advance-protein-degrading-medicines)

**![Lycia Therapeutics](https://blog.ipoprophet.com/hs-fs/hubfs/Lycia%20Therapeutics.jpg?width=339&height=181&name=Lycia%20Therapeutics.jpg)**

**Lycia Therapeutics (LYCA)** is preparing to offer **14.7 million shares at $16–$18 per share**, targeting **$249.9 million in gross proceeds at the $17 midpoint** and an implied **post-offering market capitalization of approximately $885.6 million**. The company has applied to list on the **Nasdaq Global Select Market**, with **Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities** serving as joint book-running managers. Estimated midpoint net proceeds are **$227.8 million**, excluding the underwriters’ option. 

Lycia is developing medicines designed to eliminate disease-causing proteins outside cells. Its LYTAC platform, based on work by Nobel laureate Carolyn Bertozzi, connects a target protein to a receptor that carries it into the cell’s lysosome—the machinery responsible for breaking down cellular material. The approach seeks to expand the reach of protein degradation into targets that conventional drugs may struggle to address. For investors, the appeal is the possibility of building multiple medicines from a common discovery platform, although success in one application would not establish that every program will work. 

The company also distinguishes between two types of degraders. Its classic LYTAC molecules are broken down alongside the targeted protein, while its catalytic cataLYTAC molecules are engineered to return to the cell surface and repeat the process. That recycling mechanism could allow a single drug molecule to remove multiple copies of a disease-driving protein. The commercial question is whether this translates into sufficiently durable effects to improve treatment outcomes or reduce the burden of repeated dosing.

Food allergy is Lycia’s initial focus. Lead candidate LCA-0061 targets immunoglobulin E, or IgE, an antibody involved in allergic responses. The company is studying the treatment in Phase 1 participants with elevated IgE, including people with food allergy. Its second IgE candidate, LCA-0062, uses a bispecific antibody design and remains in studies needed to support clinical entry. Advancing two approaches gives Lycia opportunities to evaluate differences in dosing and duration, but it also creates an important development decision: which candidate ultimately offers the strongest profile for patients and the most efficient path forward. 

The early human findings provide a reason to follow the story. Lycia reported a mean maximum IgE reduction of 96% in its initial LCA-0061 cohort, with additional clinical data expected in 2027. However, reducing an allergy-related biomarker does not by itself demonstrate protection against allergic reactions. The next stage of evidence needs to connect the biological effect to outcomes that matter to patients, while establishing safety across broader exposure. That distinction is central to assessing how much clinical progress the IPO valuation already anticipates. 

![LYCIA Therapeutics Financial and Pipeline Placard](https://blog.ipoprophet.com/hs-fs/hubfs/LYCIA%20Therapeutics%20Financial%20and%20Pipeline%20Placard.jpg?width=783&height=518&name=LYCIA%20Therapeutics%20Financial%20and%20Pipeline%20Placard.jpg)

The market opportunity is substantial, but the competitive standard is also rising. Lycia cites more than 33 million Americans with IgE-mediated food allergy. Xolair’s approval for reducing reactions following accidental exposure to multiple foods established an important treatment option beyond avoidance and emergency intervention. Lycia believes IgE degradation could address limitations associated with existing blockers, including dosing requirements and insufficient suppression in some patients. Those potential advantages remain development goals; demonstrating a differentiated patient benefit will matter more than showing a different mechanism alone. 

Beyond allergy, LCA-0321 is in Phase 1 development for Graves’ disease. It is designed to selectively remove the autoantibodies that stimulate excess thyroid activity. This provides a second application for the platform and a different clinical setting in which to evaluate targeted protein removal. The rationale is attractive: address a disease-driving antibody while preserving unrelated immune functions. Whether that selectivity produces meaningful and sustained improvements in thyroid function remains a clinical question. 

Financially, Lycia reported a $19.2 million net loss for the first half of 2026 and estimated September cash and securities at $138.2 million. One partnership detail deserves attention: Lilly terminated its collaboration without cause, effective February 2026. The filing does not establish that decision as a judgment on Lycia’s lead clinical programs, but investors should evaluate the company on its current pipeline and resources rather than assume the former relationship provides continuing validation or funding. 

At the proposed valuation, the investment case rests on whether Lycia can turn an intriguing mechanism and early biological activity into a differentiated medicine. Stronger patient data could support both the lead program and confidence in the broader platform. Disappointing efficacy, limited durability or emerging safety issues would make that platform premium harder to sustain. The IPO would provide substantial development capital, but the decisive value creation still lies ahead in the clinic.

[IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Lycia Therapeutics](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/lycia-therapeutics)

[linkedin-in icon](https://www.linkedin.com/company/ipo-prophet-software/) [X Twitter icon](https://www.x.com/ipoprophet)

---

[![IPO\_PROPHET\_WHITE-2](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_WHITE-2.png?width=800&height=250&name=IPO_PROPHET_WHITE-2.png "IPO_PROPHET_WHITE-2")](http://www.ipoprophet.com)

NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE.

Copyright © 2025

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Eric Friedman",
    "url" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman"
  },
  "dateModified" : "2026-10-21T19:17:28.359Z",
  "datePublished" : "2026-10-21T19:17:28.000Z",
  "headline" : "Lycia Therapeutics (LYCA) Eyes $250 Million IPO to Advance Protein-Degrading Medicines",
  "image" : [ "https://blog.ipoprophet.com/hubfs/LYCIA%20Thumbnail.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/lycia-therapeutics-lyca-eyes-250-million-ipo-to-advance-protein-degrading-medicines",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://blog.ipoprophet.com/hubfs/IPO_PROPHET_BLUE%20logo-1.png"
    },
    "name" : "ipoprophet.com"
  }
}
```